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Abstract
Background: Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell
carcinoma (RCC) are based on tumor cell lysate. The identification of the von Hippel-Lindau (VHL) gene mutations in
RCC patients provided the potential for developing a novel targeted vaccine for RCC. In this pilot study, we tested
the feasibility of vaccinating advanced RCC patients with the corresponding mutant VHL peptides.
Methods: Six patients with advanced RCC and mutated VHL genes were vaccinated with the relevant VHL
peptides. Patients were injected with the peptide mixed with Montanide subcutaneously (SQ) every 4 weeks until
disease progression or until the utilization of all available peptide stock.
Results: Four out of five evaluable patients (80%) generated specific immune responses against the corresponding
mutant VHL peptides. The vaccine was well tolerated. No grade III or IV toxicities occurred. The median overall
survival (OS) and median progression-free survival (PFS) were 30.5 and 6.5 months, respectively.
Conclusions: The vaccine demonstrated safety and proved efficacy in generating specific immune response to the
mutant VHL peptide. Despite the fact that the preparation of these custom-made vaccines is time consuming, the
utilization of VHL as a vaccine target presents a promising approach because of the lack of other specific targets
for RCC. Accordingly, developing mutant VHL peptides as vaccines for RCC warrants further investigation in larger
trials. Trial registration: 98C0139
Background
Renal cell carcinoma comprises the majority of malig-
nant kidney tumors. It is relatively rare in the United
States but its incidence has continued to rise since 1975
[1,2]. The lifetime risk of developing RCC is 1 in 11,000
[3]. Earlier detection and treatment of smaller renal
tumors has not significantly reduced the mortality rate
and about one-third of patients still present with meta-
static disease [4]. Indeed, the mortality rate has contin-
ued to rise, which necessitates looking for a better
therapeutic strategy [5,6].
RCC is one of the most resistant forms of cancers to
both radiation and chemotherapy. Recently, the multi-
targeted tyrosine kinase inhibitors Sorafenib and
Sunitinib have shown 10% and 34-44% objective
response rates, respectively, in metastatic RCC [7-9].
Accordingly, we are still in need of novel and successful
therapeutic approaches to RCC.
Clear cell renal carcinoma (CCRC) is the most com-
mon histological subtype of RCC and accounts for
about 70% of cases [10]. This tumor is often regarded as
immunogenic based on the observation of a 4% sponta-
neous regression in metastatic lesions [11-13], the abun-
dant presence of tumor infiltrating lymphocytes (TIL) in
tumor specimens, and the well-documented responses
to some immuno-cytokines (Interleukin-2 [IL-2] and
Interferon-a [IFN-a]) and vaccine therapy [14]. IL-2
and IFN-a have shown some efficacy in the metastatic
setting, with response rates of 12-20% [15-17]. Studies
of other cytokines, dendritic cell-based vaccines, and* Correspondence: khleifs@mail.nih.gov
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adoptive immunotherapy with TILs or lymphokine acti-
vated killer (LAK) cells have shown some minor benefit
[18-20]. It has been shown that patients who are able to
generate specific cytotoxic T cells (CTLs) against tumors
show better prognosis [21,22]. In addition, we and
others have demonstrated in previous clinical trials that
vaccination with peptides from different cancers pro-
duces specific immunological responses (specific CTLs)
in the corresponding cancers [23-27].
One obstacle to developing a renal cancer vaccine was to
identify an RCC tumor-specific antigen [28]. Most RCC
vaccine trials have employed unfractionated antigens
derived from the tumor cells, with the goal of eliciting spe-
cific T-cell responses against multiple undefined antigens
expressed by the tumor [28-34]. More than 60% of
patients with sporadic RCC possess a detectable somatic
mutation in the von Hippel-Lindau (VHL) gene [35,36].
Somatic mutations in VHL have been linked to the devel-
opment of sporadic CCRC and hemangioblastomas. Most
of these mutations are frameshift and the rest are mis-
sense, nonsense, or stop mutations [37-39]. Other mutated
oncoproteins such as Ras and p53 have been previously
explored as targets for vaccine therapy in humans. We
and others have found these antigens safe and able to
induce specific T cells against the mutant but not the wild
antigens [27,40-42]. Accordingly, mutated VHL represents
a novel potential target for clear cell RCC.
In this pilot study, we present our experience using
the mutated VHL peptides as a vaccine for metastatic
RCC. We show that the use of mutant VHL peptides for
targeted vaccine therapy is feasible, safe, and capable of
generating specific immunological responses, which pro-
vides incentive for further exploration in the manage-
ment of advanced RCC.
Methods
Patients and eligibility criteria
Patients with locally advanced, recurrent, progressive, or
metastatic RCC were enrolled in this pilot trial. All
patients enrolled in the trial met the protocol eligibility
criteria, including: histologically proven CCRC; tumors
expressing mutated VHL gene resulting in a new amino
acid sequence; lack of available standard systemic treat-
ment; Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1; and a life expectancy of
more than 3 months. Main exclusion criteria included:
evidence of brain metastasis; history of autoimmune dis-
ease; history of other malignancies except basal cell car-
cinoma of the skin; and pregnancy. The study protocol
was approved by the Institutional Review Boards of the
National Cancer Institute (NCI) and the National Naval
Medical Center (NNMC), Bethesda, Maryland. Written
informed consent was obtained from all patients. The
study was in compliance with the Helsinki Declaration.
Vaccine preparation
All peptides were custom-designed based on the
patient’s own tumor VHL mutation and the potential
binding affinity of the amino acid motif spanning the
mutation to the patient’s HLA (Table 1 and 2). Peptides
were designed based on the predicted binding affinity
using the BIMAS program http://bimas.cit.nih.gov/mol-
bio/hla_bind/. In case of a single residue point mutation
(peptides 3 and 4), the mutation was placed in the cen-
ter and 8 residues were included on each side, so that
every 9-mer containing the mutation would be included
in the peptide, to cover most possible epitopes that
included the mutation. In the case of peptide 2, a
shorter version of that peptide was used to avoid resi-
dues that flanked the mutation and lead to solubility
problem such as a second Cysteine (C) on the n termi-
nus, which would lead to cross-linking of peptides and
aggregation. Peptides 1 and 6 were frame shift muta-
tions, creating totally novel sequences, so as much
length as possible was used until reaching a stop codon,
or having to avoid some residues such as Cysteine (C),
as outline above. The same concept applied to peptide
5, in which the frame shift ORF ended with Arginine
(R). To have enough length, the sequence was extended
to the left by 8 of the wild type residues (unmutated); so
that every 9-mer would contain at least one of the
abnormal frame shift residues and thus no epitope in
the peptide would be contained in the wild type
sequence. Peptides were synthesized under GLP condi-
tions using an automated synthesizer (Multiple Peptide
Systems, San Diego, CA) and standard solid-phase
chemistry. The peptides were packaged in vials by the
National Institutes of Health (NIH) Clinical Center’s
Pharmacy. Safety, identity, and stability assays were con-
ducted by the NIH Clinical Center Pharmaceutical
Development Service (PDS). Assay results for each lot
were submitted to the Cancer Therapeutic Evaluation
Program (CTEP) Biological Drug Quality Assurance
Committee for review and approval prior to human use.
One hundred microliters of the patient dosage were re-
analyzed by HPLC for purity and quantity of peptide,
and sequenced by automated sequenator to confirm
identity. Immediately prior to vaccination, 1000 μg of
Table 1 VHL peptides used for vaccinations
(corresponding mutant part of peptide underlined)
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the mutant VHL peptide in 0.7 mL of normal saline
were emulsified in 1:1 ratio with the adjuvant “Monta-
nide ISA-51” (Seppic, Inc., Fairfield, NJ).
Treatment and vaccination schedule
Eligible patients received a dose of 1000 μg of the emulsi-
fied corresponding mutant VHL peptide and “Montanide
ISA-51.” Half of the total volume of the vaccine (0.7 mL)
was administered subcutaneously over each deltoid mus-
cle. Patients were observed for 1 hour in the outpatient
clinic to assess for any allergic reaction. Vaccinations
were repeated every 4 weeks until disease progression or
until the utilization of all available stock of the peptide.
Immunologic monitoring
Prior to the first vaccination, patients were apheresed to
obtain 1 × 109 peripheral blood mononuclear cells
(PBMC). This procedure was repeated every-other cycle.
In the other cycles a 100 mL of whole blood was col-
lected by phlebotomy to obtain 1 × 107 PBMCs. Lym-
phocytes obtained by apheresis were frozen and saved
for future immunologic testing. An automated Ficoll-
hypaque density gradient separation was used to obtain
the appropriate cell types for immunological assays. The
IFN-g ELISPOT assay was used to quantify mutated
VHL peptide-specific CTLs.
DC preparation used to generate DC for the ELISPOT assay
Dendritic cells (DCs) for use in the ELISPOT assays
were obtained by culturing autologous monocytes in
Granulocyte-macrophage colony-stimulating factor
(GM-CSF) and IL-4 according to widely established pro-
cedures. Briefly, frozen PBMCs were thawed and rested
for 2 hours, followed by incubation in plastic flasks for
2 hours. The nonadherent cells were then washed away
and the remaining adherent cells were cultured in 10%
fetal bovine serum (FBS) DC medium containing 100
IU/mL GM-CSF (Leukine Sargramostim, Bayer
HealthCare Pharmaceuticals, Seattle, WA) and 50 ng/
mL IL-4 (PeproTech, Inc., Rocky Hill, NJ) for 6 days at
37°C. Cultures were fed at day 3-4 by removing one-half
of the culture volume and adding an equal volume of
fresh media containing sufficient GM-CSF and IL-4 for
the entire culture volume. DCs were harvested on day 6,
pulsed with antigen for 4 hours, and then matured over-
night with 5 ng/mL Lipopolysaccharide (LPS). On day 7,
DCs were harvested, washed, and the cell suspension
volume adjusted for use in the ELISPOT assay.
ELISPOT assay
All ELISPOT assays were performed at NCI Frederick
(CLIA certified lab). The ELISPOT assay using autolo-
gous antigen-pulsed DCs was validated and approved by
the NIH Vaccine Oversight Committee. Two frozen nor-
mal donor controls with known responsive values were
run with each assay to assure quality control of the assay
results. ELISPOT assay was performed on freshly thawed
PBMCs with no in vitro expansion cultures or cytokine
addition. Autologous monocyte-derived dendritic cells
(DCs) pulsed with antigen and matured with Lipopoly-
saccharide (LPS) overnight were used as the antigen pre-
senting cells (APC). Briefly, the day before assay setup,
96-well polyvinylidene fluoride (PVDF) membrane, HTS
opaque plates (Millipore, Billerica, Massachusetts,
MSIPS40W10) were coated overnight with capture anti-
body, anti-human IFN-g (10 μg/mL) in DPBS (aIFN-g
capture antibody, 1 mg/mL Mabtech, Cat# 3420-3-1000)
at room temperature. Patient dendritic cells were har-
vested and were either pulsed with the patient’s specific
mutant VHL at 50 μg/mL, the irrelevant peptide TAX
(LLFGYPVYV, an HLA-A2 binding peptide) at 3 μg/mL,
or no peptide for 4 hours and then matured overnight
with LPS at 37°C. Antibody-coated plates were washed
the next day and blocked with 5% HuAB ELISPOT med-
ium at 37°C for approximately 2 hours; 3 × 105 freshly
thawed and 2-hour rested patients’ PBMCs and 3 × 104
Table 2 VHL mutations and HLA types in vaccinated patients
Pt DNA mutation Protein mutation HLA-A HLA-B HLA-DR HLA-DQ
1 del TT 443-444 148 Phe-Cys fsX25 02 15, 40 04, 13 03, 06
2 T-C 497 166 Val-Ala 02,11 3701, 4001 1001, 13 0501, 06
3 G-T 332 111 Ser-Ile 03, 29 14, 35 01, 13 05, 06
4 C-G 343 115 His-Asp 02 07, 40 1302, 1501 ND
5 del C 183 62 Val-Cys fsX5 03,29 35, 44 01, 13 0501, 06
6 ins C 346-347 116 Leu-Pro fsX16 02,31 40, 51 0404, 11 0301, 0302
Abbreviations: del = deletion; fs = frameshift; X = stop codon; ins = insertion.
Patient 1 had a deletion of a thymine at two nucleotides (443 and 444) that resulted in a predicted frameshift starting at codon 148 with a phenylalanine to
cysteine amino acid change, extending for 23 more codons, and ending with a premature stop codon at position 172. Patient 2 had a mutation at nucleotide
number 497 resulting in a change from thymine to cytosine which led to a substitution in valine to alanine at position 166. Patient 3 had a mutation at
nucleotide number 332 resulting in a change from guanine to thymine that led to a substitution in serine to isoleucine at position 111. Patient 4 had a mutation
at nucleotide number 343 resulting in a change from cytosine to guanine which led to a substitution from histidine to aspartic acid at position 115. Patient 5
had a deletion of a cytosine at nucleotide number 183 that resulted in a predicted frameshift starting at codon 62 with a valine to cysteine amino acid change,
extending for 3 more codons, and ending with a premature stop codon at position 66. Patient 6 had an insertion of a cytosine between two nucleotides (346
and 347) that resulted in a predicted frameshift starting at codon 116 with a leucine to proline amino acid change, extending for 14 more codons, and ending
with a premature stop codon at position 131.
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pulsed autologous DCs were used per well. The plates
were incubated for 18-20 hours at 37°C. The next day,
the plates were manually washed six times with DPBS,
0.05% Tween 20, followed by a 2-hour incubation at
room temperature with a 1:2000 dilution of the biotiny-
lated secondary antibody, anti-human IFN-g, (1 mg/mL
Mabtech, Cincinnati, OH, Cat# 3420-6-1000). After incu-
bation and four washes to remove excess antibody, a
1:3000 dilution of streptavidin alkaline phosphatase
(Mabtech, Cincinnati, OH, Cat#3310-10) was added to
each well for 1 hour followed by 4 manual washes.
Finally, The BCIP/NPT substrate, 100 ul/well, (KPL,
Gaithersburg, Maryland, Cat# 50-81-08) was added and
the reaction was stopped incubating in distilled water for
7-10 minutes, resulting in the development of spots.
Plates were dried overnight and the spots were visualized
and counted using the ImmunoSpot Imaging Analyzer
system (Cellular Technology Ltd., Cleveland, OH). The
results were calculated as: total number of experimental
spots with DC = (PBMC + pulsed DC) - (PBMC + non-
pulsed DC). From each patient, postvaccination PBMCs
were compared to prevaccination as a baseline. A positive
ELISPOT result for the patient was defined as a total
number of experimental spots in the postvaccination
sample of more than twofold above the total spots in the
prevaccination sample.
Regulatory T cells (T regs)
Cryopreserved PBMCs were thawed rapidly at 37°C. The
cells were transferred into 15 mL conical tubes (Corning,
Lowell, MA) and diluted to 10 mL by dropwise addition of
RPMI medium containing 20% FBS. The cells were pel-
leted by low-speed centrifugation at 250 xg for 10 min at
25°C. Supernatants were discarded and cell pellets resus-
pended in 5 mL of Dulbecco’s phosphate buffered saline
(D-PBS) containing 2% huAB serum to block cell surface
Fc receptors. The samples were mixed briefly and incu-
bated on ice for 15 minutes. Following incubation the cells
were pelleted by centrifugation as described before,
washed two times with D-PBS containing 2% bovine
serum albumin (BSA; D-PBS/2% BSA) and resuspended in
1 mL of D-PBS/2% BSA. The cells were counted in a
Coulter counter and adjusted to a final concentration of
10 × 106/mL in D-PBS/2% BSA. The cells (1 × 106/tube)
were stained for surface markers (CD25, CD3, and CD4)
for 20 minutes at room temperature (RT) in the dark and
washed two times with D-PBS/2% BSA.
Intracellular staining for FoxP3 was carried out using
human FoxP3 buffer prepared as described by the manu-
facturer (BD BioSciences, San Jose, CA). Briefly, following
staining of surface antigens, cells were resuspended in 2
mL of fixing solution (buffer A) and incubated for 10
minutes at RT in the dark. Cells were washed two times
with PBS/2% BSA, resuspended in 0.5 mL permeabiliza-
tion solution (buffer C) and incubated for 30 minutes at
RT in the dark. Cells were washed two times in PBS/2%
BSA and stained with anti-human FoxP3 antibody for 30
minutes at RT in the dark. Cells were then washed two
times and resuspended in 0.5 mL of PBS/2% BSA for
four-color flow cytometric analysis using the FACSCanto
cytometer (BD biosciences, San Jose, CA) running FACS
Diva acquisition software (version 6.0). Each assay con-
tained a parallel set of cells stained with relevant isotype
controls (Alexa Fluor 488 IgG1 and PE IgG1).
Flow cytometric data analysis was carried out using
FlowJo Software. T cells were identified by plotting CD3
by side scatter. CD4+ T cells were identified by further
gating the CD3+ subset by forward and side scatter and
by CD4. The regulatory CD4+ T cell subset was identified
by plotting CD25 versus FoxP3 with the quadstat setting
determined based on the isotype control tube. The quad-
rant markers of the CD25 versus FoxP3 dot plot were set
based on the isotype controls. In each case the pre and
post samples were tested side by side in the same experi-
ment and were done from frozen samples. This testing
strategy was used to minimize variability from day to
day in staining or thawing. The samples were tested in
4 independent setups over 3 days. We have included
2 internal controls in each experiment, one of those
being a frozen leukapheresis sample that has been
included in each test run as a measure of interassay
reproducibility. In the limited number of assays we have
performed using that control, the interassay CV% has
been 33% (range of 3.4 to 9.4% for CD25/FoxP3+). Elimi-
nating the outlier value of 9.4% reduces the CV to 15%.
Clinical monitoring
Patients were evaluated for toxicity and tumor response
during treatment and up to 2 years after the last vacci-
nation. Physical examination and blood profiling were
performed prior to each vaccination. Tumor response
was assessed by the appropriate imaging technique,
according to RECIST criteria, at baseline, then following
every two vaccinations during therapy and every 3
months during follow-up. Disease progression was
defined as the appearance of new lesions and/or 25%
increase of measurable lesions as evident by CT scan.
Once patients had progressed, follow-up was not
required except to document late toxicities and death.
Adverse events/toxicities were defined and graded
according to the NCI Common Toxicity Criteria.
Patients were taken off study in the case of disease pro-
gression or deterioration in performance status.
Results
Patient characteristics
Six patients with locally advanced, recurrent, progres-
sive, or metastatic RCC were enrolled in this pilot trial.
These patients had no available standard treatment or
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refused to receive one at the time of enrollment. Char-
acteristics of the treated patients are summarized in
Tables 2 and 3. All patients included in the trial had a
somatic mutation of the VHL gene (Table 2). These
mutations were single amino acid substitutions in three
patients (patients 2, 3, and 4), while patients 1 and 5
had nucleotide deletion and patient 6 had nucleotide
insertion resulting in frameshift mutations leading to
the development of novel amino acid sequences. The
patients had different HLA alleles, as shown in Table 2.
Of the six patients enrolled in the trial, five were
male and one was female (patient 2). Patients had an
average age of 62 years, with an ECOG performance
status of (0) in three patients (patients 2, 3, and 6) and
(1) in three patients (patients 1, 4, and 5; Table 3). All
patients were pretreated with multiple conventional
therapies prior to enrollment on the protocol. Radical
nephrectomy was performed in all patients and surgi-
cal resection of the metastasis was performed in all
patients except patient 4. Three patients received cyto-
kines: patient 3 received low-dose IL-2 and IFN-a for
6 months as an adjuvant therapy; patient 4 received
IFN-a for lung metastasis, and patient 5 received high-
dose IL-2 for metastatic mediastinal lymphadenopathy
followed by radical lymph node dissection and radia-
tion therapy to the mediastinum. Radiofrequency abla-
tion for lung metastases was performed twice in
patient 6. Three patients (patients 2, 3, and 5) had no
detectable disease on enrollment and the other three
patients (patients 1, 4, and 6) had distant metastases
(Table 3).
Immunological response
Patient 1 was excluded from immune analysis because
of disease progression after only two vaccinations. Four
out of the five evaluated patients (patients 2, 3, 4, and 6;
80%) generated specific immune responses against the
corresponding mutant VHL peptides (Table 4). Patient 2
had no evidence of IFN-g ELISPOT-reactive T cells
prior to the vaccination; however, the frequency of these
T cells increased dramatically after the fourth and six
vaccinations to 117 and 100 spots/106 PBMC, respec-
tively, compared with no response against the control
peptide (TAX), and remained fairly elevated (50-60
spots) during the first 12 months of follow-up and then
decreased dramatically (Figure 1A). Patient 6 had a simi-
lar immune response, having a significant increase in the
number of IFN-g ELISPOT-reactive T cells from 37
spots/106 PBMCs at baseline up to 163 spots/106
PBMCs after 10 cycles of vaccination and maintaining
the immune response during the first 8 months of fol-
low up (183 spots/106 PBMCs) before returning to base-
line (Figure 1C).
The six and four vaccinations that patients 3 and
4 received, respectively, were associated with an increase
in the IFN-g ELISPOT-reactive T cells, as shown in Figure
1B-1D. Patient 3 had a significant immune response after
the fourth vaccination (from 13 spots/106 PBMCs at base-
line up to 183 spots/106 PBMC); however, despite main-
taining the immune response during the first 2 months of
follow-up (160 spots/106 PBMCs), the number of reactive
T cells then returned to baseline (Figure 1B). The number
of IFN-g ELISPOT-reactive T cells in patient 4 increased
Table 3 Patient characteristics of the study population
Pt Age Gender PS Stage at diagnosis Prevaccination therapy Extent of disease at first vaccination
1 61 M 1 II SX2 Lung and mediastinal LN metastasis
2 66 F 0 III SX2 NED
3 40 M 0 III SX3, IFN-a, IL-2 NED
4 71 M 1 IV SX1, IFN-a Lung and abdominal wall metastasis
5 65 M 1 III SX2, IL-2, RX1 NED
6 69 M 0 III SX4, RFAX2 Lung and liver metastasis
Abbreviations: Pt = patient; PS = performance status; NED = no evidence of disease; M = male; F = female; LN = lymph nodes; S = surgery; IFN-a = Interferon-a;
IL-2 = Interleukin-2; Rx = radiation; RFA = radiofrequency ablation.
Table 4 Clinical and immunological outcome
Patient Cycles received Off-therapy reason Off-study status PFS OS Immune response
1 2 P P 2 17 Neg
2 10 PSC NED 88 + 88 + Pos
3 6 R R 6.5 87 + Pos
4 4 P P 4 8 Pos
5 11 PSC R 13.5 30.5 Neg
6 18 PSC S 57 + 57 + Pos
Abbreviations: P = progressive disease; R = recurrent disease; S = stable disease; NED = no evidence of disease; PSC = peptide stock completed; PFS =
progression-free survival in months; OS = overall survival in months (both PFS and OS were calculated from the on-study date until progression, death, or last
known follow-up marked as (+); Pos = positive immune response; Neg = negative immune response.
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after the second and fourth vaccinations (from 0 at base-
line up to 233/106 PBMCs and 390/106 PBMCs, respec-
tively); however, this patient was lost to follow-up for
additional immune endpoints (Figure 1D).
Regulatory T cells (T regs)
T regulatory cells (CD4+CD25+FoxP3+) were measured
in the peripheral blood of the five evaluable patients
(patients 2, 3, 4, 5, and 6) prevaccination and following
each vaccination (Figure 2). No difference was found in
the T regulatory cells frequencies in the postvaccination
samples compared with prevaccination in four patients
who demonstrated an immune response (patients 2, 3,
4, and 6). On the other hand, patient 5 who had no
immune response to the corresponding peptide had a
significant elevation in T regulatory cells in the post
vaccination samples.
Safety and toxicity
The vaccine was well tolerated. No grade III or IV toxi-
city occurred. The most common systemic adverse
events were grade I and II fatigue (83% of patients) and
local skin reaction in the form of mild skin redness and
swelling (83% of patients), which resolved in less than
72 hours. No signs or symptoms of autoimmune disease
were observed up to 88 months of follow-up.
Clinical response
Patients received a total of 51 vaccinations. One of the
treated patients did not complete the first four vaccina-
tions (patient 1). This patient had extensive lung metas-
tases and was removed from the study after two
vaccinations because of rapid deterioration of perfor-
mance status and disease progression. The other five
patients received at least four vaccinations. Patient 3
had recurrent disease after six vaccinations. It is note-
worthy that this patient underwent right adrenalectomy
followed by subcarinal node resection and remained
without any recurrence 87 months after enrollment on
the study despite having no further therapy. Patient 4
was removed from the study after four vaccinations due
to disease progression. The other three patients (patients
Figure 1 Immune responses measured by ELISPOT assay. ELISPOT results for all patients who had positive immune responses to the
corresponding VHL peptide (spots/106 PBMC) in purple compared with the control peptide (TAX) in red: patient 2 (panel A); patient 6 (panel C);
patient 3 (panel B); and patient 4 (panel D). Pre = prevaccination sample; Post V = postvaccination sample marked by the vaccine number; and
F/u = follow up sample marked in months (ms) from the last post vaccine sample.
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2, 5, and 6) received 10, 11, and 18 vaccinations, respec-
tively, until the peptide stock was exhausted. Patients 2
and 6 completed the study and remained without dis-
ease recurrence (patient 2) or progression (patient 6) for
88, and 57 months, respectively, after starting on the
study; both patients had no further conventional therapy
after finishing the study. Patient 5 had recurrent disease
during follow-up with cerebral metastases (Table 4).
The median OS and median PFS for all six patients
were 30.5 and 6.5 months, respectively.
Discussion
The identification of the VHL gene and its critical role in
renal malignancy has provided insight into the pathogen-
esis of sporadic clear cell renal carcinoma. It has also
provided the potential for developing novel targeted
therapies, including specific vaccines. In this pilot study
we evaluated the feasibility of vaccination against mutant
VHL peptides corresponding to the patients’ own tumor
mutations. We also tested the ability of this vaccine to
generate a specific immune response against these muta-
tions. The number of vaccinations varied among the six
patients because it was dependent not only on the status
of disease progression but also on the amount of the pep-
tides available for use. We found that these custom-made
mutant VHL peptide antigens were able to induce strong,
specific immune responses detected by ELISPOT assay in
four of the five evaluable vaccinated patients (80%). The
immune responses of the three responding patients who
had long-term follow-up share the same trend described
as: 1) an increase in VHL peptide-specific T-cell fre-
quency from baseline compared with the control peptide
(TAX); 2) maintenance of the increased VHL-specific
T-cell frequency throughout therapy; and 3) a return of
the immune response to baseline after completion of the
treatment.
Although cells other than T cells, such as NK cells
and monocytes, present in PBMC utilized in the ELI-
SPOT assays can secrete IFN-g, the majority of IFN-g
secreting cells in the assays are T cells. Patients’ autolo-
gous DCs were loaded with the specific peptides (10-17-
mer VHL peptides) served as APC. Therefore, these
peptides were presented in the appropriate context to
stimulate T cell reactivity (MHC restricted peptides).
Additionally, the number of IFN-g secreting cells in
response to the VHL-peptides increased after vaccina-
tion. This data demonstrates that the IFN-g response
measured in the ELISPOT is due to the induction of
memory cells, and therefore T cells, to vaccination. As
such, it is unlikely that any cells other than T cells are
involved in the IFN-g secretion. It would be interesting
to distinguish between reactivity of CD8+ versus CD4+
T cells and if there are changes in these subsets, espe-
cially with those patients who demonstrated promising
clinical out comes. However, for the purposes of this
study, general T cell reactivity in response to vaccination
Figure 2 Regulatory T cells (T regs). The percentage of T regulatory cells (CD4+CD25+FoxP3+) measured in the peripheral blood of the
evaluable patients (patient 2, 3, 4, 5, and 6) pre and postvaccination. The postvaccination samples were taken during the last vaccination visit for
every patient except patient 3 whom the last available T regs sample was during vaccination 5.
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was an appropriate measure to first assess if the vaccina-
tion could elicit an immune response to mutated self-
antigen. Normally, the frequency of self-reactive T cells
is quite low due to multiple mechanisms of central and
peripheral tolerance. Findings from this pilot study
demonstrate that we can elicit immunity to VHL pep-
tides and thus provides the foundation for future studies
to elucidate the particular immune responses generated
by this vaccine.
Some cancer vaccine trials showed an increase of T
regulatory cells which may be due to the progressive
disease status or the use of certain cytokines, such as
IL-2 [43,44]. Here we found that there was no increase
in T regulatory cells in the postvaccination samples
compared with prevaccination in all patients who
demonstrated an immune response. The increase in T
regulatory cells might have contributed to the limited
efficacy of the vaccine in the only patient who failed to
demonstrate an immune response. This also may indi-
cate that the simple vaccination with antigens and adju-
vants without cytokines may contribute less to the
generation of T regulatory cells.
Vaccinating with mutant VHL peptides was found to
be generally safe. The toxicities were all grade I or II
and resolved spontaneously. This was a small pilot trial
and was not powered to test the vaccine for clinical effi-
cacy; however, despite the advanced disease status of
these patients, we found that their median OS and med-
ian PFS were 30.5 and 6.5 months, respectively. Three
of the six vaccinated patients are still alive (57, 87, and
88 months after starting on the trial) despite having no
further conventional therapy, which is extremely unu-
sual for patients with advanced RCC; interestingly, all
three patients had a positive immune response to the
corresponding peptide.
Conclusions
In conclusion, we believe that vaccination with mutant
VHL peptides is safe and effective in generating a speci-
fic immune response to the corresponding peptides.
Manufacturing these custom-made peptides is time-con-
suming since it takes a cumulative 6-9 months to
sequence the gene, manufacture the peptide, package it
in vials, and conduct the appropriate required stability
testing. This may pose practicality challenges in using
such vaccination methods in advanced disease, consider-
ing the short life expectancy. Furthermore, as we have
seen in this trial, the immune responses induced by
these peptides along with adjuvant administered subcu-
taneously–as easy and practical as they may be–reverse
gradually as soon as vaccinations are completed.
Accordingly, we believe that such treatment needs to be
continued in order to maintain meaningful immune
response or use certain cytokines that can prolong the
immune response such as IL-15 or GM-CSF [45,46].
That having been said, targeting VHL still provides a
unique opportunity for a specific vaccine against RCC,
especially in early disease, since there are very few
known antigens in RCC. This trial draws attention to a
novel therapeutic approach in RCC treatment that
needs to be investigated further in larger clinical trials.
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